ArticleMedical hypotheses2021
Supportive therapy during COVID-19: The proposed mechanism of short-chain fatty acids to prevent cytokine storm and multi-organ failure.
Article in Medical hypotheses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Gut microbiomes-host immune response and organ dysfunction across the gut-lung, gut-brain, and gut-liver axes.Frontiers in cellular and infection microbiology · 2026Review
- Partially hydrolyzed guar gum attenuates symptoms and modulates the gut microbiota in a model of SARS-CoV-2 infection.Gut microbiome (Cambridge, England) · 2025Article
- The Link between Inflammation, Lipid Derivatives, and Microbiota Metabolites in COVID-19 Patients: Implications on Eating Behaviors and Nutritional Status.International journal of molecular sciences · 2024Review
- Review
- Bibliometric analysis of intestinal microbiota and lung diseases.Frontiers in cellular and infection microbiology · 2024Article
- Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy.International journal of molecular sciences · 2023Review
- Impact of COVID-19 on Nonpulmonary Critical Illness: Prevalence, Clinical Manifestations, Management, and Outcomes.Clinics in chest medicine · 2023Review
- COVID-19 contact tracking based on person reidentification and geospatial data.Journal of King Saud University. Computer and information sciences · 2023Article
- Butyrate dictates ferroptosis sensitivity through FFAR2-mTOR signaling.Cell death & disease · 2023Article
- Immune and metabolic cross-links in the pathogenesis of comorbid non-alcoholic fatty liver disease.World journal of gastroenterology · 2023Review
- Butyrate limits the replication of porcine epidemic diarrhea virus in intestine epithelial cells by enhancing GPR43-mediated IFN-III production.Frontiers in microbiology · 2023Article
- The Gut Microbiome of Children during the COVID-19 Pandemic.Microorganisms · 2022Review
- Role of Micronutrients and Gut Microbiota-Derived Metabolites in COVID-19 Recovery.International journal of molecular sciences · 2022Review
- Probiotics: A gut response to the COVID-19 pandemic but what does the evidence show?Clinical nutrition ESPEN · 2022Review
- Role of Short-Chain Fatty Acids Produced by Gut Microbiota in Innate Lung Immunity and Pathogenesis of the Heterogeneous Course of Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2022Review
- Anti-Inflammatory Function of Fatty Acids and Involvement of Their Metabolites in the Resolution of Inflammation in Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The world is currently facing the COVID-19 pandemic that is taking a heavy toll on several countries. While many infected patients have a good prognosis, in some cases the progression can be serious and even lead to death. The commonly seen complications are a cytokine storm and multi-organ failure that require intensive care. The mortality of critically ill patients depends on age, sex, immune state or co-morbidities. There is an urgent need to discover a biomarker to identify early on patients at risk of developing serious complications and to find an effective treatment that could prevent disease progression and critical states. Recent investigations have pointed to the possible contribution of intestinal dysbiosis to the pathophysiology of COVID-19. Herein, we hypothesize that butyrate, a short-chain fatty acid initially produced by the gut microbiota, could be administered as supportive therapy to prevent immune system activation and disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.